Medicenna's Bizaxofusp Shows Survival Data in Recurrent Glioblastoma at SNO 2026
Event summary
- Medicenna's bizaxofusp survival data in recurrent glioblastoma selected for oral presentation at SNO 2026.
- Presentation scheduled for November 13, 2026, by Dr. Nicholas A. Butowski of UCSF.
- Bizaxofusp has Fast Track and Orphan Drug designations in the U.S. and Europe.
- Data uses propensity score-weighted external control arm in intended Phase 3 population.
The big picture
Medicenna's presentation at SNO 2026 comes as the neuro-oncology field increasingly focuses on targeted immunotherapies for glioblastoma. The company's ability to leverage this data could determine its strategic positioning against larger players in the immunotherapy space. Bizaxofusp's proprietary delivery mechanism and regulatory designations may provide a competitive edge, but execution will be key.
What we're watching
- Clinical Validation
- Whether bizaxofusp's survival data will position it as a competitive option in recurrent glioblastoma.
- Partnership Potential
- The pace at which Medicenna can secure pharma partnerships based on these results.
- Regulatory Pathway
- How Fast Track designation may accelerate bizaxofusp's path to market approval.
Related topics